• AMD, or age-related macular degeneration, is the most common reason for people in the United States to lose their eyesight
  • AMD affects the macula at the back of your eye. The macula is the part of the retina that lets you see images directly in front of you, like faces or words on a page
  • There are 2 types of AMD: wet and dry
  • In dry AMD, changes occur in the cells of the macula. Drusen build up in this area. As the size and number of these deposits increase, so does your risk of developing wet AMD
  • Dry AMD is the slow form of the disease, with changes you may not notice over time
  • About 85% of people with AMD have dry AMD
  • In wet AMD, abnormal blood vessels suddenly leak fluid in the back of the eye without advance notice. This will cause permanent vision loss if left undetected.
  • About 10%-15% of people with dry AMD progress to the more aggressive wet AMD
  • Wet AMD destroys the sharp, pinpoint vision needed to see objects clearly. You may lose your ability to read a book or computer screen, drive, watch television, or do other daily tasks because of distortion or blind spots in your central vision
  • Wet AMD develops in people who already have dry AMD
  • The chances of dry AMD advancing to the more severe wet stage increases as dry AMD progresses over time. In some cases, your chances of progressing from dry AMD to wet AMD within the next 5 years can be greater than 50%
  • Earlier detection of wet AMD lets your doctor intervene sooner and quickly begin treatment to preserve your vision.

FDA Indication for Use

The ForeseeHome is intended for use in the detection and characterization of central and paracentral metamorphopsia (visual distortion) in patients with age-related macular degeneration, as an aid in monitoring progression of disease factors causing metamorphopsia including but not limited to choroidal neovascularization (CNV). It is intended to be used at home for patients with stable fixation.

The ForeseeHome AMD Monitoring Program is only available by physician order and is intended to be used as an addition to regular eye exams.

The ForeseeHome AMD Monitoring Program is covered by Medicare, subject to its coverage requirements for the test, to assess patients with dry AMD who are at risk of developing wet AMD.